Navigation Links
The North American Menopause Society (NAMS) reassures many women
Date:2/27/2012

(February 23, 2012) A great deal has been learned in the ten years since the first results emerged from the Women's Health Initiative (WHI). Hormone therapy (HT) remains the most effective treatment available for menopausal hot flashes and night sweats. However, there is a growing body of evidence that formulation, route of administration, timing of therapy and duration of therapy may produce different effects.

It is essential to evaluate a personal benefit-risk profile for each woman considering HT. Individual factors contributing to the HT decision include the severity of menopausal symptoms and effect on quality of life.

The absolute risks of HT in healthy women ages 50 to 59 are low. In contrast, long-term HT or HT initiation in older women is associated with greater risks.

SUMMARY

  • The recommendation for duration of therapy differs for Estrogen Progestogen Therapy (EPT) in women with a uterus, and Estrogen Therapy (ET) in women who have had a hysterectomy.

  • For EPT, duration is limited by the increased risk of breast cancer associated with more than 3 to 5 years of use. ET has a more favorable benefit-risk profile with no apparent increase in risk of breast cancer during an average of 7 years of use, a finding that allows more flexibility in duration of therapy.

  • Individualizing is still key in the decision to use HT and should incorporate the woman's health and quality of life priorities as well as her personal risk factors, such as risk of blood clots, heart disease, stroke, and breast cancer.

  • For relief of hot flashes, women with a uterus should take EPT so that a progestogen will protect the lining of the uterus from the cancer-promoting effects of estrogen alone.

  • Low-dose vaginal ET is advised when symptoms are limited to vaginal dryness or discomfort with intercourse.

  • Neither ET nor EPT increases the risk of heart disease in healthy women under age 60 years or within 10 years of menopause. The risk of stroke can be increased but is considered rare in the 50s.

  • Women with premature or early menopause who are otherwise appropriate candidates can use HT until the average age of natural menopause (age 51). Longer duration of treatment can be considered if needed for symptom management.

  • There is a lack of safety data supporting the use of HT in breast cancer survivors.

  • Both ET delivered through the skin and low-dose oral ET have been associated with lower risks of blood clots and stroke than standard doses of oral estrogen, but confirmation of benefits in randomized trials is not yet available.

Additional research is needed to understand the different effects of ET and EPT and how they apply to individual women.


'/>"/>

Contact: Carolyn Develen
carolyn@menopause.org
440-442-7657
The North American Menopause Society (NAMS)
Source:Eurekalert

Related medicine news :

1. Toys"R"Us, Inc. Expands its Support of Autism Speaks Throughout North America
2. Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
3. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
4. Sleep HealthCenters to Sponsor North East Sleep Society 2010
5. Lafarge North America Recognized by IBI and NBCH for Health & Productivity Leadership
6. Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region
7. St. Josephs Hospital-North Opens in North Tampa
8. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
9. Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery
10. Warning: Immigrating to North America may foster smoking in children
11. Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: